Skip to main content
MAQAF logo

Atlas Arteria Limited (MAQAF) Stock: Price, Forecast & Analyst Target

Atlas Arteria Limited (MAQAF) — price $2.66 (0.00%), as of the Nov 19, 2026 trading session; market cap $3.87B.

Educational signal · not a buy or sell recommendation · How to read this

$2.66 $0.00 (0.00%) Market Cap $3.87B

Atlas Arteria Limited · MAQAF

The company focuses on infrastructure assets within the industrial sector, generating revenue through toll collections.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$2.66
Change on the day0.00%
Market capitalisation$3.87B—
Price / earnings (trailing)20.03
Shares traded on the day100

Price & events

Other perspectives

Council score for Atlas Arteria (MAQAF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Moderate
Debt/Equity Neutral
ROE Weak
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Atlas Arteria (MAQAF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Atlas Arteria Limited (MAQAF) is the company analyzed here. In Q2 FY2026 it reported revenue of A$74M and net income of A$116M. The market values it at $3.87B.

2 · Latest results

What do the latest results show for Atlas Arteria (MAQAF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of A$74M. Against analyst estimates the company has EPS beat 0 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026A$74MA$116MA$0.08 (diluted)
Q4 FY2025A$82MA$152MA$0.10 (diluted)
Q2 FY2025A$78MA$107MA$0.07 (diluted)
Q4 FY2024A$75MA$222MA$0.15 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Atlas Arteria (MAQAF)?

Short answer · as of

The distress and quality screens read Altman Z 1.43 · Piotroski F 6. Trailing ratios: ROE 4.9% · ROA 3.8% · current ratio 0.75 · earnings yield 4.8% · free-cash-flow yield 10.9%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.43 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
4 · What to check next?

What should you watch next at Atlas Arteria (MAQAF)?

Short answer · as of

Current published price targets run low $4.75 · high $5.31 · consensus $5.03 · median $5.03 against a quoted price of $2.66 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$4.75 – $5.31
Consensus target
$5.03
Median target
$5.03

Consensus record · Captured .

Measured against a quoted price of $2.66 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MAQAF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MAQAF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: MAQAF Stock

These answers are editorial: 1 of these 8 answers is drawn from the MAQAF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is MAQAF a good stock to buy?

Stock Expert AI does not rate MAQAF buy, sell or hold. Atlas Arteria Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MAQAF stock price today?

The last price recorded for Atlas Arteria Limited (MAQAF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MAQAF price target?

The analyst consensus price target for Atlas Arteria Limited (MAQAF), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for MAQAF?

Atlas Arteria faces several risks inherent to the toll road industry. Economic downturns can reduce traffic volume, impacting toll revenue.

What are the key factors to evaluate for MAQAF?

Evaluate MAQAF on fundamentals, analyst consensus, and risk factors. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. metropolitan area, would directly boost toll revenue. Not financial advice.

How frequently does MAQAF data refresh on this page?

MAQAF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MAQAF's recent stock price performance?

Atlas Arteria Limited (MAQAF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Stable revenue stream from toll collections. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MAQAF overvalued or undervalued right now?

The trailing P/E of Atlas Arteria Limited (MAQAF) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 16 figures on this page — 12 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.